P282 Bacterial co-infections in Mucormycosis infected COVID-19 patients: experience from a tertiary care center in India

IF 1.4 Q4 MYCOLOGY
Neha Sharad, Smriti Srivastava, Aparna Ningombam, V. Kiro, Sharin Varma, Sharad Srivastav, R. Malhotra, P. Mathur
{"title":"P282 Bacterial co-infections in Mucormycosis infected COVID-19 patients: experience from a tertiary care center in India","authors":"Neha Sharad, Smriti Srivastava, Aparna Ningombam, V. Kiro, Sharin Varma, Sharad Srivastav, R. Malhotra, P. Mathur","doi":"10.1093/mmy/myac072.P282","DOIUrl":null,"url":null,"abstract":"Abstract Poster session 2, September 22, 2022, 12:30 PM - 1:30 PM During the second wave of COVID-19 in India, there was a deluge in Mucormycosis cases; which posed a serious threat as both conditions require extended hospital stay thus serving as an ideal setting for secondary infections. Objectives 1. To ascertain the prevalence and anti-microbial profile of hospital-acquired secondary infections in COVID- 19 patients with Mucormycosis. 2. To evaluate the outcome in these patients and compare it with the outcome of COVID-19 patients with Mucormycosis but without any other secondary infection. Methods A 2-month retrospective observational study was conducted, where we compared outcomes in two groups of COVID-19 patients with Mucormycosis, one group being patients with secondary infections and the other group including patients without secondary infections. A total of 180 samples from suspected cases of Mucormycosis, that underwent evaluation by conventional methods, KOH mount and cultures on SDA, were included. Fungal pathogens were identified from the positive cultures, based on macroscopic and microscopic features, as per standard Mycological methods. Secondary infections inpatients were studied based on conventional bacteriological culture, microbiological profile, along-with identification and antibiotic susceptibility by VITEK 2. PCT and CRP values were also compared. The outcome was then evaluated. Data analysis was done using SPSS V-20. Results A total of 55 patients out of 140 patients, tested positive for Mucormycosis, either by KOH, culture or both. Rhizopus arrhizus was the most common isolate identified. A total of 12/55 (21.8%) people with Mucormycosis developed secondary infections during their stay in the hospital, bloodstream infection being the most common (7/15; 46.67%). Overall, gram-negative (GN) organisms were more common (11/16; 68.75%), in comparison to Gram Positives (GP) (5/16; 31.25%), but the most common organism isolated was Enterococcus faecium (5/16; 31.25%), followed by Klebsiella pneumoniae (4/16) and E. coli (4/16). A total of 4/5 isolates (80%) of Enterococcus faecium were multi-drug resistant (MDR) and two of them were vancomycin-resistant. In all, 10/11 GN isolates (90.9%) were MDR, high resistance to carbapenems was observed, nine out of 11(81.81%) isolates were resistant to imipenem and eight (72.72%) were resistant to meropenem. A total of 3/12 (25%) patients succumbed to their infection in the group with secondary infections, after an average length of stay of 23.33 days. The most common cause of death in these patients was septic shock. A total of 8/43 (18.6%) succumbed to their infection in the group without any secondary infection at an average stay of 9.12 days in the hospital. CRP was found to be consistently elevated, this biomarker might not have a predictive value for bacterial infections in COVID-19 but PCT had a positive predictive value for the secondary bacterial infections overall (P-value <.001). Length of stay in hospital co-related with the development of secondary infection and mortality (P-value <.001). Conclusion Culture-based testing should be carried out before the administration of anti-microbials. PCT can be used as a guiding tool. Controlled use of antibiotics along with periodic surveillance and hand hygiene practices will immensely contribute to infection control.","PeriodicalId":18325,"journal":{"name":"Medical mycology journal","volume":"200 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/mmy/myac072.P282","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MYCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Poster session 2, September 22, 2022, 12:30 PM - 1:30 PM During the second wave of COVID-19 in India, there was a deluge in Mucormycosis cases; which posed a serious threat as both conditions require extended hospital stay thus serving as an ideal setting for secondary infections. Objectives 1. To ascertain the prevalence and anti-microbial profile of hospital-acquired secondary infections in COVID- 19 patients with Mucormycosis. 2. To evaluate the outcome in these patients and compare it with the outcome of COVID-19 patients with Mucormycosis but without any other secondary infection. Methods A 2-month retrospective observational study was conducted, where we compared outcomes in two groups of COVID-19 patients with Mucormycosis, one group being patients with secondary infections and the other group including patients without secondary infections. A total of 180 samples from suspected cases of Mucormycosis, that underwent evaluation by conventional methods, KOH mount and cultures on SDA, were included. Fungal pathogens were identified from the positive cultures, based on macroscopic and microscopic features, as per standard Mycological methods. Secondary infections inpatients were studied based on conventional bacteriological culture, microbiological profile, along-with identification and antibiotic susceptibility by VITEK 2. PCT and CRP values were also compared. The outcome was then evaluated. Data analysis was done using SPSS V-20. Results A total of 55 patients out of 140 patients, tested positive for Mucormycosis, either by KOH, culture or both. Rhizopus arrhizus was the most common isolate identified. A total of 12/55 (21.8%) people with Mucormycosis developed secondary infections during their stay in the hospital, bloodstream infection being the most common (7/15; 46.67%). Overall, gram-negative (GN) organisms were more common (11/16; 68.75%), in comparison to Gram Positives (GP) (5/16; 31.25%), but the most common organism isolated was Enterococcus faecium (5/16; 31.25%), followed by Klebsiella pneumoniae (4/16) and E. coli (4/16). A total of 4/5 isolates (80%) of Enterococcus faecium were multi-drug resistant (MDR) and two of them were vancomycin-resistant. In all, 10/11 GN isolates (90.9%) were MDR, high resistance to carbapenems was observed, nine out of 11(81.81%) isolates were resistant to imipenem and eight (72.72%) were resistant to meropenem. A total of 3/12 (25%) patients succumbed to their infection in the group with secondary infections, after an average length of stay of 23.33 days. The most common cause of death in these patients was septic shock. A total of 8/43 (18.6%) succumbed to their infection in the group without any secondary infection at an average stay of 9.12 days in the hospital. CRP was found to be consistently elevated, this biomarker might not have a predictive value for bacterial infections in COVID-19 but PCT had a positive predictive value for the secondary bacterial infections overall (P-value <.001). Length of stay in hospital co-related with the development of secondary infection and mortality (P-value <.001). Conclusion Culture-based testing should be carried out before the administration of anti-microbials. PCT can be used as a guiding tool. Controlled use of antibiotics along with periodic surveillance and hand hygiene practices will immensely contribute to infection control.
P282感染COVID-19毛霉病患者的细菌合并感染:来自印度三级医疗中心的经验
摘要海报会议2,2022年9月22日,下午12:30 - 1:30在印度的第二波COVID-19期间,毛霉病病例大量出现;这构成了严重的威胁,因为这两种情况都需要延长住院时间,从而成为继发感染的理想环境。目标1。目的了解新冠- 19型毛霉病患者医院获得性继发感染的流行情况及抗菌谱。评估这些患者的预后,并将其与COVID-19伴毛霉菌病但无其他继发感染的患者的预后进行比较。方法采用为期2个月的回顾性观察研究,比较两组新冠肺炎伴毛霉菌病患者的预后,一组为继发感染患者,另一组为无继发感染患者。采用常规方法、KOH mount法和SDA培养法对疑似毛霉病病例的180份样本进行评估。根据宏观和微观特征,按照标准真菌学方法,从阳性培养物中鉴定真菌病原体。对住院患者继发感染进行常规细菌学培养、微生物学分析、VITEK 2鉴定及药敏分析。同时比较PCT和CRP值。然后对结果进行评估。数据分析采用SPSS V-20软件。结果140例患者中有55例毛霉病阳性,KOH、培养或两者均阳性。阿根霉是最常见的分离物。共有12/55(21.8%)毛霉菌病患者在住院期间发生继发感染,血液感染是最常见的(7/15;46.67%)。总体而言,革兰氏阴性(GN)菌更为常见(11/16;68.75%),与革兰氏阳性(GP)相比(5/16;31.25%),但最常见的是粪肠球菌(5/16;其次是肺炎克雷伯菌(4/16)和大肠杆菌(4/16)。共有4/5株(80%)屎肠球菌为多药耐药,其中2株对万古霉素耐药。共有10株GN菌株耐多药(MDR),占90.9%,对碳青霉烯类耐药高,对亚胺培南耐药9株(81.81%),对美罗培南耐药8株(72.72%)。继发感染组3/12(25%)患者感染死亡,平均住院时间23.33 d。这些患者最常见的死亡原因是感染性休克。无继发感染组共有8/43(18.6%)死于感染,平均住院时间为9.12 d。发现CRP持续升高,该生物标志物可能对COVID-19细菌感染没有预测价值,但PCT对继发性细菌感染总体具有阳性预测价值(p值< 0.001)。住院时间与继发感染和死亡率相关(p值< 0.001)。结论应用抗菌药物前应进行培养试验。PCT可作为一种指导工具。控制抗生素的使用以及定期监测和手部卫生习惯将极大地有助于感染控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medical mycology journal
Medical mycology journal Medicine-Infectious Diseases
CiteScore
1.80
自引率
10.00%
发文量
16
期刊介绍: The Medical Mycology Journal is published by and is the official organ of the Japanese Society for Medical Mycology. The Journal publishes original papers, reviews, and brief reports on topics related to medical and veterinary mycology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信